| AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models HM Weir, RH Bradbury, M Lawson, AA Rabow, D Buttar, RJ Callis, ... Cancer research 76 (11), 3307-3318, 2016 | 206 | 2016 |
| Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation RA Ward, C Brassington, AL Breeze, A Caputo, S Critchlow, G Davies, ... Journal of medicinal chemistry 55 (7), 3285-3306, 2012 | 184 | 2012 |
| Acoustic mist ionization platform for direct and contactless ultrahigh-throughput mass spectrometry analysis of liquid samples I Sinclair, M Bachman, D Addison, M Rohman, DC Murray, G Davies, ... Analytical chemistry 91 (6), 3790-3794, 2019 | 110 | 2019 |
| Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis PS Shirude, P Madhavapeddi, M Naik, K Murugan, V Shinde, ... Journal of Medicinal Chemistry 56 (21), 8533-8542, 2013 | 108 | 2013 |
| Identification and characterization of dual inhibitors of the USP25/28 deubiquitinating enzyme subfamily JD Wrigley, G Gavory, I Simpson, M Preston, H Plant, J Bradley, ... ACS chemical biology 12 (12), 3113-3125, 2017 | 76 | 2017 |
| Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase T Klein, N Vajpai, JJ Phillips, G Davies, GA Holdgate, C Phillips, ... Nature communications 6 (1), 7877, 2015 | 75 | 2015 |
| Discovery of cofactor-specific, bactericidal Mycobacterium tuberculosis InhA inhibitors using DNA-encoded library technology HH Soutter, P Centrella, MA Clark, JW Cuozzo, CE Dumelin, MA Guie, ... Proceedings of the National Academy of Sciences 113 (49), E7880-E7889, 2016 | 53 | 2016 |
| Biophysical methods in drug discovery from small molecule to pharmaceutical G Holdgate, S Geschwindner, A Breeze, G Davies, N Colclough, ... Protein-Ligand Interactions: Methods and Applications, 327-355, 2013 | 53 | 2013 |
| Biophysical methods in early drug discovery G Holdgate, K Embrey, A Milbradt, G Davies ADMET and DMPK 7 (4), 222-241, 2019 | 32 | 2019 |
| Small-molecule degraders beyond PROTACs—challenges and opportunities JM Kastl, G Davies, E Godsman, GA Holdgate SLAS DISCOVERY: Advancing the Science of Drug Discovery 26 (4), 524-533, 2021 | 25 | 2021 |
| Acoustic mist ionization mass spectrometry (AMI-MS) as a drug discovery platform I Sinclair, G Davies, H Semple Expert opinion on drug discovery 14 (7), 609-617, 2019 | 24 | 2019 |
| MDM4 binds ligands via a mechanism in which disordered regions become structured MC Sanchez, JG Renshaw, G Davies, PN Barlow, M Vogtherr FEBS letters 584 (14), 3035-3041, 2010 | 22 | 2010 |
| A high-throughput screening triage workflow to authenticate a novel series of PFKFB3 inhibitors SA St-Gallay, N Bennett, SE Critchlow, N Curtis, G Davies, J Debreczeni, ... SLAS DISCOVERY: Advancing Life Sciences R&D 23 (1), 11-22, 2018 | 15 | 2018 |
| Unified software solution for efficient SPR data analysis in drug research G Dahl, S Steigele, P Hillertz, A Tigerström, A Egnéus, A Mehrle, M Ginkel, ... SLAS DISCOVERY: Advancing Life Sciences R&D 22 (2), 203-209, 2017 | 9 | 2017 |
| Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFα Fab fragment and human TNFα WM Abbott, M Snow, S Eckersley, J Renshaw, G Davies, RA Norman, ... Bioscience Reports 33 (4), e00060, 2013 | 9 | 2013 |
| A perspective on the discovery of enzyme activators A Turberville, H Semple, G Davies, D Ivanov, GA Holdgate SLAS Discovery 27 (8), 419-427, 2022 | 7 | 2022 |
| High-Throughput mechanism of inhibition G Davies, H Semple, M McCandless, J Cairns, GA Holdgate SLAS DISCOVERY: Advancing the Science of Drug Discovery 26 (2), 248-256, 2021 | 5 | 2021 |
| Grouping concentration response curves by features of their shape to aid rapid and consistent analysis of large data sets in high throughput screens G Davies, J Vincent, MJ Packer, D Murray SLAS Discovery 27 (4), 272-277, 2022 | 4 | 2022 |
| Abstract DDT01-03: Discovery and pre-clinical pharmacology of AZD9496: An oral, selective estrogen receptor down-regulator (SERD) H Weir, M Lawson, R Callis, M Hulse, M Tonge, G Davies, G Walker, ... Cancer Research 75 (15_Supplement), DDT01-03-DDT01-03, 2015 | 2 | 2015 |
| Protein-Ligand Interactions G Holdgate, S Geschwindner, A Breeze, G Davies, N Colclough, ... Humana Press, Totowa, NJ, 2013 | 2 | 2013 |
Holdgate GASenior Principal Scientist, AstraZeneca在 astrazeneca.com 的电子邮件经过验证
Holdgate GASenior Principal Scientist, AstraZeneca在 astrazeneca.com 的电子邮件经过验证